Sequenom, DNA Chip Research, Mitsui, and NovusGene, Wellcome Trust Sanger Institute, National Institute on Aging, Department of Energy s Joint Genome Institute, and GenData and Celera Diagnostics | GenomeWeb

Sequenom in Danger of Being Demoted to Small-Cap Market

Sequenom risks receiving a letter from the Nasdaq exchange warning the company of possible delisting if it fails to close above $1 by the end of trading on Sept. 17.

“There seems to be a threshold out there in the market place that is keeping us from closing above $1,” said a Sequenom spokesperson. “We’ve hit above $1 a few times in the past week or so, but we haven’t been able to close above $1.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.